G2 Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial

作者： J. O'Shaughnessy , C. Osborne , J. Pippen , M. Yoffe , D. Patt

DOI: 10.1016/S1359-6349(09)72040-3

关键词: Triple-negative breast cancer 、 Carboplatin 、 Oncology 、 In patient 、 Poly ADP ribose polymerase 、 Gemcitabine 、 Internal medicine 、 PARP1 、 Medicine